Cogent Biosciences, Inc. Balance Sheet
COGT / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
Cogent Biosciences, Inc. had $938M in total assets and $636M in shareholders' equity as of FY2025. Total debt was $223M against $312M in cash, resulting in a $89M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M | $242.2M | $37.4M | $55.7M | $28.3M |
| Accounts Receivable | - | - | - | - | - | - | $2.0M | $1.7M | $830.0K |
| Current Assets | $910.4M | $296.5M | $270.8M | $265.0M | $222.6M | $244.9M | $40.6M | $81.0M | $42.4M |
| PP&E (Net) | $5.5M | $6.5M | $8.3M | $7.8M | $1.7M | $134.0K | $1.9M | $3.3M | $4.1M |
| Total Assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M | $250.9M | $49.4M | $85.9M | $49.1M |
| Current Liabilities | $64.0M | $55.7M | $38.2M | $26.8M | $17.1M | $13.1M | $13.2M | $24.9M | $11.2M |
| Total Debt | $222.9M | - | - | - | - | - | - | - | - |
| Shareholders' Equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M | $234.7M | $31.8M | $60.2M | -$48.8M |